menu
    • menu

    Company profile for Altimmune

    NEW Drugs in Dev: 10
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Altimmune is a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcell), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™ and NasoShield™).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AltimmuneUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    910 Clopper Road Suite 201S, Gaithersburg, MD 20878
    Telephone
    Telephone
    (240) 654-1450
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://altimmune.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/vaxin-inc-
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/hashtag/altimmune?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Altimmune To Participate In Upcoming Investor Conferences
    Altimmune To Participate In Upcoming Investor Conferences

    27 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/27/3301939/0/en/altimmune-to-participate-in-upcoming-investor-conferences.html

    GLOBENEWSWIRE
    27 May 2026
    Share Share
    Altimmune Reports Q1 2026 Financial Results And Business Update
    Altimmune Reports Q1 2026 Financial Results And Business Update

    13 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/13/3293891/0/en/altimmune-announces-first-quarter-2026-financial-results-and-business-update.html

    GLOBENEWSWIRE
    13 May 2026
    Share Share
    Altimmune To Present Pemvidutide Results In MASH At EASL
    Altimmune To Present Pemvidutide Results In MASH At EASL

    13 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/13/3293871/0/en/altimmune-to-present-results-of-pemvidutide-in-mash-in-an-oral-presentation-and-multiple-poster-presentations-at-easl-congress-2026.html

    GLOBENEWSWIRE
    13 May 2026
    Share Share
    Altimmune Reports Q1 2026 Results and Business Update on May 13
    Altimmune Reports Q1 2026 Results and Business Update on May 13

    06 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/06/3288706/0/en/altimmune-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026.html

    GLOBENEWSWIRE
    06 May 2026
    Share Share
    Altimmune Closes $225M Oversubscribed Offering
    Altimmune Closes $225M Oversubscribed Offering

    27 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7211246

    FIRSTWORD PHARMA
    27 Apr 2026
    Share Share
    Altimmune Presents Hearing Loss Gene Therapy Long-Term Data
    Altimmune Presents Hearing Loss Gene Therapy Long-Term Data

    23 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7205880

    FIRSTWORD PHARMA
    23 Apr 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search